Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Lutterotti

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Neurology(R) Neuroimmunology & Neuroinflammation|September 21, 2016
Restoring immune tolerance in neuromyelitis optica: Part IIAmit Bar-Or, Larry Steinman, Jacinta M Behne, et al.
Cell|September 4, 2018
Memory B Cells Activate Brain-Homing, Autoreactive CD4<sup>+</sup> T Cells in Multiple SclerosisIvan Jelcic, Faiez Al Nimer, Jian Wang, et al.
Cell|October 22, 2020
HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple SclerosisJian Wang, Ivan Jelcic, Lena Mühlenbruch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in GlioblastomaJian Wang, Tobias Weiss, Marian C Neidert, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 16, 2021
Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating DiseasesKathrin Schanda, Patrick Peschl, Magdalena Lerch, et al.
Plos One|November 14, 2013
Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million peopleFahmy Aboul-Enein, Thomas Seifert-Held, Simone Mader, et al.
Therapeutic Advances in Neurological Disorders|August 23, 2021
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Der Nervenarzt|July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Multiple Sclerosis and Related Disorders|July 7, 2020
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patientsDaniel H Whittam, Alvaro Cobo-Calvo, A Sebastian Lopez-Chiriboga, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Neurology(R) Neuroimmunology & Neuroinflammation|September 21, 2016
Restoring immune tolerance in neuromyelitis optica: Part IIAmit Bar-Or, Larry Steinman, Jacinta M Behne, et al.
Cell|September 4, 2018
Memory B Cells Activate Brain-Homing, Autoreactive CD4<sup>+</sup> T Cells in Multiple SclerosisIvan Jelcic, Faiez Al Nimer, Jian Wang, et al.
Cell|October 22, 2020
HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple SclerosisJian Wang, Ivan Jelcic, Lena Mühlenbruch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in GlioblastomaJian Wang, Tobias Weiss, Marian C Neidert, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 16, 2021
Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating DiseasesKathrin Schanda, Patrick Peschl, Magdalena Lerch, et al.
Plos One|November 14, 2013
Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million peopleFahmy Aboul-Enein, Thomas Seifert-Held, Simone Mader, et al.
Therapeutic Advances in Neurological Disorders|August 23, 2021
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Der Nervenarzt|July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Multiple Sclerosis and Related Disorders|July 7, 2020
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patientsDaniel H Whittam, Alvaro Cobo-Calvo, A Sebastian Lopez-Chiriboga, et al.
Pageof 7